Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024
(in million U.S. dollars)
Global oncology revenue by top ten pharmaceutical companies 2017 and 2024
The top ten pharmaceutical companies based on global oncology revenue in 2017 and the projected revenue of those top 10 companies in 2024 include Roche, Celgene and Bristol-Meyers Squibb, to name a few. At that time Roche was estimated to be the top pharmaceutical company based on oncology revenue. Roche’s oncology products generated an estimated 27.5 billion U.S. dollars in 2017. It is expected that Roche’s oncology products will generate 27.8 billion U.S. dollars by 2024.

Oncology pharmaceuticals

Among U.S. oncology brands in 2016, Clegene’s Revlimid was the top revenue generating oncology brand. Revlimid is a drug used to treat multiple myeloma, myelodysplastic syndromes and mantel cell lymphoma. Globally, Revlimid was also among the top oncology products in 2017. However, it is expected to be surpassed by Merck & Co.’s Keytruda by 2024. This data reveals the current existing oncologics, however, there are many new drugs in development. In the U.S., it was expected that 2018 will yield the largest number of cancer drugs in development in recent history.

Cancer prevalence and treatments

The U.S. and Europe have the highest prevalence of diagnosed cancer cases globally as of 2018. Among all types of cancer, trachea, bronchus and lung cancer are the deadliest, followed by liver cancer. The availability of cancer treatments varies around the world. As of 2017, the U.S. and Germany had the largest number of new medications for cancer available between 2012 and 2016. At that same time, China and India had only smaller number of cancer drugs available.
Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024
(in million U.S. dollars)
20172024
---
---
---
---
---
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

* Projections.

Open this statistic in...
Global oncology revenue by top ten pharmaceutical companies 2017 and 2024
The top ten pharmaceutical companies based on global oncology revenue in 2017 and the projected revenue of those top 10 companies in 2024 include Roche, Celgene and Bristol-Meyers Squibb, to name a few. At that time Roche was estimated to be the top pharmaceutical company based on oncology revenue. Roche’s oncology products generated an estimated 27.5 billion U.S. dollars in 2017. It is expected that Roche’s oncology products will generate 27.8 billion U.S. dollars by 2024.

Oncology pharmaceuticals

Among U.S. oncology brands in 2016, Clegene’s Revlimid was the top revenue generating oncology brand. Revlimid is a drug used to treat multiple myeloma, myelodysplastic syndromes and mantel cell lymphoma. Globally, Revlimid was also among the top oncology products in 2017. However, it is expected to be surpassed by Merck & Co.’s Keytruda by 2024. This data reveals the current existing oncologics, however, there are many new drugs in development. In the U.S., it was expected that 2018 will yield the largest number of cancer drugs in development in recent history.

Cancer prevalence and treatments

The U.S. and Europe have the highest prevalence of diagnosed cancer cases globally as of 2018. Among all types of cancer, trachea, bronchus and lung cancer are the deadliest, followed by liver cancer. The availability of cancer treatments varies around the world. As of 2017, the U.S. and Germany had the largest number of new medications for cancer available between 2012 and 2016. At that same time, China and India had only smaller number of cancer drugs available.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Oncology"
  • Cancer facts
  • Oncology market
  • Companies
  • Cancer drugs
  • Research and development
  • Immuno-oncology
  • Treatment types
  • Physicians and patients
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.